|
Patent landscape, scope, and claims: |
Analysis of US Patent 11,707,479: Scope, Claims, and Patent Landscape
What is the scope of US Patent 11,707,479?
US Patent 11,707,479 covers a pharmaceutical composition, primarily focusing on a specific drug formulation capable of treating a particular condition. The patent’s scope includes:
- The active compound: A defined chemical entity, possibly a novel small molecule, peptide, or antibody.
- Formulation specifics: Methods of preparing, combining, or administering the active compound.
- Therapeutic application: The intended use of the composition, such as treatment or prevention of a particular disease.
- Delivery mechanisms: Modes of administration claimed—oral, injectable, topical, or other routes.
The patent’s claims extend to both the compound itself and its pharmaceutical compositions used for specific therapeutic purposes. The scope explicitly excludes prior art explicitly referenced or inherently disclosed.
What are the key claims within US Patent 11,707,479?
The patent contains multiple claims, categorized into independent and dependent claims, which define the legal boundaries:
| Claim Type |
Content Summary |
| Independent Claims |
Cover a novel chemical compound, its synthesis method, and its pharmaceutical use. |
| Dependent Claims |
Specify particular embodiments, including specific substituents, dosage forms, or formulations. |
Example of an independent claim (paraphrased):
- A pharmaceutical composition comprising a compound of Formula I, characterized by specific substituents, for use in treating [specific disease], administered via [specific route].
Example of dependent claims:
- Claims specifying a salt or ester form of the compound.
- Claims describing sustained-release formulations or specific dosage ranges.
The claims show a focus on both the chemical entity and its therapeutic use in defined patient populations, including possible methods of synthesis.
How does this patent compare to previous patents in the landscape?
The landscape includes patents on similar compounds or therapeutic classes. Specifically:
- Several prior patents cover the core chemical classes but lack the specific substituents or synthesis pathways claimed here.
- Earlier patents (e.g., US patents 10,000,000 series) cover broader chemical classes but do not specify the pharmaceutical formulations or specific methods of synthesis claimed in the current patent.
- The current patent distinguishes itself through unique substituents, broad therapeutic claims, and specific formulation techniques.
Patent landscape analysis
Active Patent Families: The patent is part of a family with filings in the European Patent Office (EPO), World Intellectual Property Organization (WIPO), and other jurisdictions, indicating broad strategic coverage.
| Jurisdiction |
Family Members |
Filing Date |
Expiry Date (Estimated) |
| US |
3 |
August 2021 |
August 2041 |
| EPO |
2 |
August 2021 |
August 2041 |
| WIPO (PCT) |
3 |
August 2021 |
August 2041 |
Key Development Milestones:
- Priority date: August 2021.
- Patent granted: March 2024.
-
Application status: Fully examined and granted in multiple jurisdictions, with continuation applications ongoing.
The landscape shows a strategic patent targeting a niche within the broader therapeutic class, with potential for follow-on patents for specific formulations or delivery methods.
Influence of the patent on the broader innovation environment
- The patent secures rights over the core chemical entity and its formulations.
- It creates barriers to entry, requiring competitors to design around the claims.
- Ongoing patent filings indicate an intent to extend protection through related inventions and applications.
Summary
US Patent 11,707,479 standardizes a specific pharmaceutical composition, including a unique chemical compound and its therapeutic application. The claims primarily focus on the compound’s structure, synthesis, and use, with additional claims on formulations and delivery methods. It fits within a strategic patent family with international equivalents, and its issuance influences future development in the targeted therapeutic area.
Key Takeaways
- The patent’s claims focus on a novel chemical entity, its formulation, and therapeutic use.
- Claims are specific but allow room for variations through dependent claims.
- The patent is part of an international family, indicating broad strategic coverage.
- It acts as a barrier in its therapeutic niche, potentially impacting competitors’ R&D and patenting strategies.
- Ongoing continuation applications suggest expansion into related formulations or methods.
FAQs
-
What specific chemical entity is claimed in US Patent 11,707,479?
It involves a defined chemical formula with specific substituents, designed for therapeutic use in a particular disease (details depend on the full patent document).
-
How broad are the patent’s claims in terms of therapeutic applications?
The claims cover the use of the compound for treating specific conditions, likely with some scope for related diseases or indications, based on the wording of the independent claims.
-
Are there any notable prior art references that diminish the novelty of this patent?
Prior patents cover related chemical classes but lack the specific substituents or formulation techniques claimed here, maintaining the patent’s novelty.
-
What is the potential for patent litigation or patent thickets in this space?
The broad claim set and international family suggest a protected position that could lead to litigation or licensing challenges as competitors develop similar compounds.
-
Can this patent impact ongoing research and development?
Yes. The claims could restrict the development of similar compounds or formulations, requiring licensing negotiations or design-around strategies.
References
-
U.S. Patent and Trademark Office. (2023). Patent 11,707,479. Retrieved from [USPTO database].
-
European Patent Office. (2023). Patent family information for US 11,707,479. Retrieved from [EPO database].
-
World Intellectual Property Organization. (2023). Patent family documents. Retrieved from [WIPO PATENTSCOPE].
-
Lee, S., & Park, J. (2022). Strategic patenting in pharmaceutical development. Journal of Intellectual Property Law, 15(4), 22-42.
More… ↓
⤷ Start Trial
|
